A Phase 3 interventional study of MIBI scintigraphy and F18-choline PET in Parathyroid Adenoma, Hyperparathyroidism and F18-choline, sponsored by Centre Francois Baclesse. Completed at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Centre Francois Baclesse · Phase 3, Interventional, and Diagnostic
The investigators hypothesize that positron emission tomography with fluorocholline (F18-choline PET) will reduce the proportion of unnecessary invasive surgery decisions and that the higher cost of positron emission tomography versus MIBI scintigraphy (Tc99m-sestaMIBI ) will be offset by lower cost in terms of type. surgery performed wisely and complications.
63 studies on the registry are indexed under Parathyroid Neoplasms; 19 are open to participants now.
This study's enrollment of 59 is close to the median of 60 across 38 interventional studies indexed under Parathyroid Neoplasms.
Browse Parathyroid Neoplasms studies →Centre Francois Baclesse is the lead sponsor of 110 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Performing a MIBI scintigraphy, then, in the case of negativity, a F18-choline PET
Diagnostic Test: MIBI scintigraphy · Diagnostic Test: F18-choline PET
Realization of F18-choline PET, then, in case of negativity, a MIBI scintigraphy
Diagnostic Test: MIBI scintigraphy · Diagnostic Test: F18-choline PET
Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
Also known as: F18-choline PET
Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
Also known as: MIBI scintigraphy
Compare, between each diagnostic strategy, the proportion of patients for whom the first-line imaging technique guided the surgical procedure wisely
Time frame: Up to 2 months
Estimate the diagnostic performance of each strategy by measuring sensitivity and specificity
Time frame: Up to 2 months
Evaluate post-surgical complications by measuring tne number of infections, hematoma
Time frame: Up to 2 months
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.